Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Auschwitz Committee wants German auction of Holocaust items scrapped - 2Artemis II's moon-bound astronauts capture Earth's brilliant blue beauty as they leave it behind
- 3Germany's Lufthansa enters race for stake in Portuguese airline TAP
- 4Vietnam rethinks its flood strategy as climate change drives storms and devastation
- 5Hilary Duff releases 'Mature,' her 1st song in 10 years
- This Overlooked Predator Is Running Out of Time—Why Conservationists Are Racing to Save the Striped Hyena
- Figure out How to Amplify the Resale Worth of Your Kona SUV
- Ergonomic Office Seats for Work spaces
- Fundamental Venture The board Apparatuses for Remote Groups
- Congo declares its latest Ebola outbreak over, after 43 deaths
- The Manual for Decent European Urban communities in 2024
- Blue Origin launches huge rocket carrying twin NASA spacecraft to Mars
- Manual for 6 famous sorts of cheddar
- Foreign military officials can become Israel's ambassadors, senior IDF commander tells 'Post'
